New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases produce parallel oncogenic signals and share many molecular targets, including activators of cap-dependent translation. Here, we show that PIM kinase expression can affect the clinical outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated resistance is refractory to mTORC1 inhibition. However, both PIM-and AKT-expressing lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade of the translation initiation complex is highly effective against these tumors. The therapeutic effect of blocking cap-dependent translation is mediated, at least in part, by decreased production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1/2 kinases themselves. Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors.
Brief Definitive Report
Molecular signaling pathways are promising targets in cancer therapy, but resistance often thwarts clinical success. Acquired mutations of drug targets, feedback activation of oncogenic signals, and redundant signaling pathways are important causes of resistance, and cocktails of multiple inhibitors are considered one potential solution (Sawyers, 2007) . For example, the rapa mycin analogues (rapalogs) are potent inhibi tors of mTORC1 with promising antitumor activity against some cancers (Dancey, 2010) . mTORC1 blockade by rapamycin interferes with the activation of capdependent transla tion and exploits a cancer cell's dependence on increased translation of certain oncoproteins (Wendel et al., 2007; Sonenberg and Hinnebusch, 2009) . In animal models, rapamycin dramatically enhances the effectiveness of DNAdamaging chemotherapy (Wendel et al., 2004) . However, in clinical trials in nonHodgkin's lymphoma (NHL), rapalogs have failed to show durable clinical benefit for most patients (Dancey et al., 2009; Hess et al., 2009; Smith et al., 2010) . The causes are illunderstood, and new insight should enable better therapies. Abbreviations used: ABC, activated B cell; CLL/SLL, chronic lymphocytic leukemia/ small lymphocytic lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; GC, germinal center; HPC, hematopoietic progenitor cell; MCL, mantle cell lym phoma; NHL, nonHodgkin's lymphoma; OS, overall survival; shRNA, small hairpin RNA; TMA, tissue microarray; TTE, time to event.
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
and Table S2 ). The same analyses of 116 DLBCL patients treated between 1989 and 2008 showed differences that did not reach statistical significance in OS (P = 0.1678) or TTE (P = 0.4461; Fig. 1, H and I; and Table S3 ). Similarly, another group re cently reported association of PIM2 with outcome in DLBCL (GómezAbad et al., 2011) . All but three of the DLBCL pa tients were treated with upfront chemotherapy, including doxorubicin in 88% of patients. Statistical analyses for each PIM kinase analyzed as a single variable or coexpression of PIM1/2 in FL and DLBCL are available in Table S4 and Table S5 .
PIM promotes the development of drug-resistant lymphomas in vivo
To study the function of PIM kinase activity in lymphomas, we modeled its effects in murine models of aggressive pre-B cell (Adams et al., 1985) and indolent follicular lymphoma (Egle et al., 2004) . In brief, we used adoptive transfer of Eµ-Myc or VavPBcl2 transgenic hematopoietic progenitor cells (HPCs; Wendel et al., 2004) expressing AKT, Pim2, or vector into lethally irradiated, syngeneic wildtype recipients and monitored the animals for lymphomas (Fig. 2 A) . PIM1 and PIM2 are highly homologous, therefore we did not ex amine PIM1 separately (Nawijn et al., 2011) . Both Pim2 (n = 12; P < 0.0001) and AKT (n = 30; P < 0.0001) accelerated disease onset compared with controls (n = 64; P = 0.1209 Pim2 vs. AKT; Fig. 2 A; Verbeek et al., 1991; Wendel et al., 2004) . Immunoblotting confirmed expression of AKT and Pim2 and translational activation by both kinases as indicated by increased phosphorylation of 4EBP1 and ribosomal pro tein S6 (Fig. 2 C) . Histopathology and surface marker analysis revealed that Pim2 and AKTexpressing tumors were indis tinguishable from aggressive pre-B cell lymphomas ( Fig. 2 B and unpublished data). The VavPBcl2 model is a genetically and pathologically accurate model of FL, and both Pim2 (P < 0.0001) and AKT (P = 0.0292) accelerated development compared with vector of a slowly proliferating B cell lymphoma with splenic involvement and increased peripheral lympho cyte counts (unpublished data). Hence, Pim2 and AKT acti vate protein translation and promote lymphomagenesis in mouse models of aggressive and indolent lymphoma.
Next, we examined how PIM and AKT affect treatment responses in vivo. In brief, we transplanted aggressive Eµ-Myc lymphomas with defined genetic alterations into nonirradi ated recipients, and then treated with 10 mg/kg doxorubicin once lymphomas had developed (Wendel et al., 2004) . A side byside comparison of chemosensitive Eµ-Myc/Arf / tumors (control; n = 44) with Eµ-Myc/Pim2 (n = 6), or Eµ-Myc/AKT (n = 30) lymphomas, revealed early relapse and shortened sur vival with Pim2 and AKTexpressing tumors (Fig. 2 D ; P = 0.0145 Pim2 vs. Arf, P<0.0001 AKT vs. Arf). Rapamycin alone had little effect on any tumor (Fig. 2 E) . However, combi nations of rapamycin with doxorubicin caused dramatic re sponses in AKT lymphomas, but had no effect on Pim2expressing tumors (Pim2, n = 13; AKT, n = 21; control, n = 28; P < 0.0001, Pim vs. AKT; Fig. 2 F) . Hence, chemoresistance caused by AKT but not by Pim2 is readily reversed by mTORC1 inhibition.
Multiple oncogenic signaling pathways cause aberrant activation of protein translation in cancer cells, including RAS, PI3K-AKT, MAPK, and the PIM kinases (Sonenberg and Hinnebusch, 2009 ). The PIM kinases were identified in a ge netic screen. They promote cell growth and survival and share many targets, including regulators of protein translation, with the better studied AKT/PKB kinases (Nawijn et al., 2011) . PIM kinases are induced by cytokine signals and, unlike AKT do not require posttranslational modifications for activity (Fox et al., 2003) . Activation of capdependent translation via derepression of the translation factor eIF4E is a critical output of both AKT and PIM signaling in cancer (Wendel et al., 2004; Hammerman et al., 2005) . PIM1 and PIM2 are widely expressed in cancer; PIM3 is restricted to certain solid tumors (Nawijn et al., 2011) . Accordingly, PIM inhibitors have been developed, but clinical trials were terminated early because of cardiac toxicity (Morwick, 2010) . Our study explores the clinical impact of PIM1/2 expression in NHL, and we demon strate that inhibition of capdependent translation is an effec tive therapy alternative to combinations of kinase inhibitors.
RESULTS AND DISCUSSION
PIM1 and PIM2 are widely expressed in NHL and affect the outcome of follicular lymphoma (FL) We found widespread expression of PIM1 and PIM2 across multiple subtypes of NHL. Immunohistochemical staining of tissue microarrays (TMA) reveals that PIM1 is expressed in 87% of mantle cell lymphomas (MCL; Hsi et al., 2008) , 76% of chronic lymphocytic leukemia/small lymphocytic lym phoma (CLL/SLL; Chen et al., 2009) , and 48 and 42% of dif fuse large B cell lymphoma (DLBCL) and FL, respectively. PIM2 is detected in 42% of DLBCL and between 24% and 30% of FL, MCL, and CLL/SLL (Fig. 1 , A-E; and Table S1 ). Similarly, PIM1/2 mRNA levels are highly expressed in the activated B cell (ABC) type, rather than the germinal center (GC) type of DLBCL (Alizadeh et al., 2000; Rosenwald et al., 2003; Basso et al., 2005; Lenz et al., 2008; unpublished data) . PIM2 is abundantly expressed across a panel of human lym phoma cell lines, whereas PIM1 is coexpressed in some, and immunoblots on mouse pro-B cells and EµMyc lymphomas confirm PIM1/2 induction by cytokine signals (Fox et al., 2003; unpublished data) .
PIM expression affects the outcome of therapy in follic ular lymphoma patients. First, we analyzed pretreatment follic ular lymphoma samples from 66 patients treated at Memorial SloanKettering Cancer Center (MSKCC) between 1984 and 2000 (Table S2 ). All but five of these patients received chemotherapy, including doxorubicin in 61% of patients. In this cohort, time to event (TTE) and overall survival (OS) were significantly better for patients whose tumors were PIMnegative (PIM, no PIM1 or PIM2) compared with patients whose tumors were PIMpositive (PIM+, PIM1, PIM2, or both; P = 0.0113 for TTE, P = 0.0372 for OS for PIM+ vs. PIM tumors). The mean age was 60.9 and 52.6 yr for the groups, respectively; however, age alone did not ex plain the difference in outcome (P = 0.13; Fig. 1 , F and G;
Br ief Definitive Repor t are rapidly enriched under rapamycin treatment (Fig. 3 , A and inset). Pim2 causes partially rapamycininsensitive increases in the phosphorylation of 4EBP1, eIF4E, and Bad, whereas S6 phosphorylation remains sensitive to rapamycin (Fig. 3 B) . The capbinding protein eIF4E is the ratelimiting factor in capdependent translation that is activated by phosphoryla tion of its inhibitor 4EBP1 and can be further enhanced by direct eIF4E (S209) phosphorylation (Wendel et al., 2007; Sonenberg and Hinnebusch, 2009 ). Profiles of ribosome load ing on mRNAs (polysome profiles) indicate the efficiency of protein translation. Polysome profiles on parental and Pim2 expressing EµMyc/Tsc2 / lymphoma cells reveal a partially rapamycinrefractory increase of protein translation in Pimexpressing lym phomas (Fig. 3 C) . Accordingly, both Pim and direct expression of eIF4E protect against rapamycin and have a similar effect in cells treated with the TOR kinase inhibitors PP242 and Torin1 (Feldman et al., 2009; Thoreen et al., 2009; Fig. 3 D) . By comparison, a small hairpin RNA (shRNA) against BAD showed no protective effect dur ing rapamycin treatment (unpublished data). To examine whether PIM expressing tumors remained depen dent on capdependent translation, we tested the antiproliferative effects of a constitutively active inhibitor of eIF4E (4E-BP1-4A) that acts down stream from mTORC1 (Rong et al., 2008) . Surprisingly, parental Eµ-Myc/ Tsc2 / lymphomas and Pim2 ex pressing Eµ-Myc/Tsc2 / cells were equally sensitive to direct inhibition of eIF4E and cells expressing 4EBP1/ GFP were rapidly depleted from a mixed population, but had little effect in nontransformed cells (Fig. 3 E and unpublished data) . Hence, PIM2 readily bypasses mTORC1 inhibition, but is unable to protect lymphoma cells from the effects of direct transla tion inhibition.
PIM-expressing lymphomas remain dependent on eIF4E and cap-dependent translation
We examined how PIM bypasses mTORC1 inhibition in rapamycinsensitive Eµ-Myc/Tsc2 / lymphomas . TSC2 is the Rheb GTPaseactivating protein and acts as a negative regulator of mTORC1 activation by Rheb (Tee et al., 2003; Mavrakis et al., 2008) . Accordingly, tumors arising in Tsc2 deficient animals show an mTORC1dependent and rapamycinsensitive activation of capdependent translation. Pim2 expression in Eµ-Myc/Tsc2 / cells abrogates rapamy cin sensitivity, and in mixed populations of parental and Pim2/ GFPexpressing Eµ-Myc/Tsc2 / cells the Pim2/GFP cells absence of translational activation (Wendel et al., 2004; Fig. 4 C) . Moreover, silvestrol is also far superior to two recently devel oped PIM inhibitors in human lymphoma cells. In brief, we tested SGI1776, the only PIM inhibitor that has entered clinical trials (biochemical IC 50 for PIM1, 15 nM; PIM2, 363 nM), and SGI1773 (biochemical IC50 for PIM1, 2 nM; PIM2, 43 nM); both drugs were developed and supplied to us by SuperGen Inc. (Morwick, 2010) . The PIM kinase inhibi tors induced cell death in various human lymphoma cells at concentrations between 1-10 µM; in comparison, silvestrol had the same cell kill at 1-10 nM (Fig. 4 D) . In animals, sil vestrol was able to reverse Pim2mediated rapamycin resistance
Silvestrol is a small molecule inhibitor of capdependent translation Silvestrol was identified in a screen for inhibitors of eIF4A, the RNA helicase component of the translation initiation complex that is thought to unwind an mRNA's 5UTR (Bordeleau et al., 2008) . Consistent with our genetic data using a constitutive 4E-BP1 construct, we found that Pim2 is unable to protect Eµ-Myc/Tsc2 / cells from silvestrol alone or in combination with rapamycin (Figs. 4, A andB) . Silvestrol kills parental and Pim2expressing Eµ-Myc/Tsc2 / cells at nanomolar concentrations in vitro, but is inactive against 3T3 fibroblasts and Myc/Bcl2 lymphomas tumors that arise in the 
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oncoproteins including c-MYC, MCL1 and Cyclin D1 (Sonenberg and Hinnebusch, 2009 ). Treatment of PIM expressing human lymphoma cells with the PIM inhibitor SGI1773 (10 µM) somewhat reduced Cyclin D1, but had no effect on c-MYC or MCL1 (Fig. 4 F) . In contrast, silvestrol (10 nM) caused almost complete loss of Cyclin D1, c-MYC, and MCL1. Moreover, silvestrol completely ablated the ex pression of both PIM1 and PIM2 kinases (Fig. 4 F) . Silvestrol had similar effects on PIM expression in DoHH2 and SuDHL10 (Fig. 4 G) . This is consistent with the known short halflife of PIM1 and PIM2 and indicates that PIM ex pression is controlled, at least in part, by capdependent transla tion (Hoover et al., 1997 (Cencic et al., 2009 ). In brief, animals bearing parental Tsc2deficient tumors cells (n = 9) remained relapse free for up to 3 wk after rapamycin, whereas Eµ-Myc/Tsc2 / / Pim2 lymphomas (n = 9) showed no response or relapsed early (P = 0.0006; Fig. 4 E) . The addition of silvestrol to rapa mycin treatment restored rapamycin sensitivity, and Eµ-Myc/ Tsc2 / Pim2 tumorbearing animals remained relapse free for as long as sensitive controls (P = 0.7219; Fig. 4 E) . Hence, the translation inhibitor silvestrol has good activity active against human lymphoma cells and can overcome PIM mediated resistance in vivo.
Translation is required to maintain expression of oncoproteins including c-MYC and PIM
In cancer the activation of capdependent protein trans lation by AKT or PIM ensures the expression of shortlived (Sonenberg and Hinnebusch, 2009). Both kinases can limit the effectiveness of chemotherapy, and although the effects of AKT are readily reversed by blocking mTORC1 and transla tion with rapamycin (Wendel et al., 2004) , PIMexpressing tumors remain refractory and are able to maintain trans lation in an mTORC1independent manner. However, PIM expressing tumor cells continue to depend on translational activation, and they are therefore sensitive to small molecules that directly target the translation initiation complex down stream from mTORC1. For example, silvestrol, an inhibitor of the eIF4A RNA helicase (Bordeleau et al., 2008) , is highly active against PIMexpressing tumors (Fox et al., 2003; Hammerman et al., 2005) . PIM kinase inhibitors are under development, and to date only SGI1776 has entered phase I evaluation. However, its efficacy against multiple tumors and lymphoma was limited, and the trial was terminated because of cardiac toxicity (SuperGen press release November 10, 2010). Hence, PIM expression is a significant clinical problem in lymphoma and a new therapeutic strategy is needed. We identify a therapeutic strategy that is highly effective against PIMexpressing lymphomas. Both the AKT and PIM kinases control regulators of capdependent translation 
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In vivo treatment studies. Treatment studies with doxorubicin and/or rapamycin were as previously described (Wendel et al., 2004; Mavrakis et al., 2008) . In brief, 10 6 primary lymphoma cells were injected into the tail vein of 10-12wkold female C57BL/6 mice. Upon the formation of well palpable tumors, the animals were treated with rapamycin (LC Laboratories; 4 mg/kg, i.p.), doxorubicin (SigmaAldrich; 10 mg/kg, i.p.), or a combina tion of both. Eµ-Myc/Arf / tumors, which are homogeneous in respect to p53 status, were used as controls where indicated. For treatment studies with Eµ-Myc/Tsc2 / tumor cells, 10-12wkold female C57BL/6 mice were injected with 250,000 tumor cells. Rapamycin was given as above, and silves trol was dosed as previously described (Bordeleau et al., 2008) , given at 0.2 mg/kg daily for 7 d. After treatment, the mice were monitored by palpa tion and blood smears stained with Giemsa (Thermo Fisher Scientific). Tumorfree and OS data were analyzed in the KaplanMeier format using the logrank (MantelCox) test for statistical significance.
Cell culture, competition, and viability assays. Eµ-Myc/Tsc2 / and Eµ-Myc/p53 / tumor cells were cultured in B cell media (1:1 DMEM/ IMDM, with 10% fetal bovine serum, penicillin/streptomycin, and lglutamine) on feeder layers consisting of irradiated NIH3T3 cells. Competition assays used the MSCVIRESGFP vector ± the indicated genes (Pim1, Pim2, and eIF4E) or the shRNA vector MLP (Mavrakis et al., 2008) for shBad (see below). GFP expression was assessed through FACS analysis (Guava EasyCyte; Millipore). Experiments were repeated three or more times and averaged based on fold change in the percentage of GFP + cells before and after treat ment with drug or vehicle. In competition time point experiments, cells were treated with drug or vehicle on day 0 for 24 h and tracked for GFP expres sion daily. Human lymphoma cell lines were cultured in RPMI1640 or DME supplemented with 10% fetal bovine serum, penicillin/streptomycin, and lglutamine. Cell viability was assessed with CellTiterGlo reagent (Promega). IC 50 values were determined from viability curves and represent a mean value from 3-4 curves per cell line. The 4E-BP14A (in MSCVIRESGFP) vector was a gift from the laboratory of N. Rosen (SloanKettering Institute, New York, NY) and was sequence confirmed to contain mutation to alanine at resi dues T37, T46, S65, and T70. Cytokine stimulation was performed for 6 or 12 h with 400 pg/ml recombinant mouse IL3 (Fitzgerald Industries) and 10 ng/ml recombinant mouse IL6 (Fitzgerald Industries). Puromycin selec tions were performed for 2 d at a concentration of 2 µg/ml.
In vitro treatment studies. Rapamycin (LC Laboratories) was dissolved in ethanol vehicle and stored as 10 mM stock solution protected from light at 20°C. It was diluted in icecold ethanol before use at the indicated concen trations in the results and compared with 1:1,000 ethanoltreated vehicle controls. Silvestrol was stored as 10mM stock solution in DMSO at 80°C and diluted in DMSO before use at the indicated concentrations in the re sults. SGI1773 and SGI1776 were provided by SuperGen Inc. and were stored as 10mM stock solutions in DMSO at 20°C. Comparisons for sil vestrol and the Pimkinase inhibitors were to 1:1,000 DMSOtreated vehicle controls. For detecting drug effects by immunoblot, cells were treated with 10 nM rapamycin for 4 h, 10 nM silvestrol for 24 h, or 10 µM SGI1773 for 24 h.
Polysomal profiling. Sucrose density gradient centrifugation was used to separate the ribosome fractions. 15 min before collection, cycloheximide (100 µg/ml) was added to the culture medium. Cells were washed in icecold PBS containing 100 µg/ml cycloheximide and harvested. Cell pellets were resuspended in polysome lysis buffer (5 mM TrisHCl, pH 7.5, 2.5 mM MgCl 2 , 1.5 mM KCl, 2 mM DTT, 0.5% Triton X100, 0.5% sodium deoxy cholate, 100 µg/ml cycloheximide, RNAsin inhibitor, and protease and phosphatase inhibitors). Cells were incubated on ice for 15 min, and then centrifuged at 10,000 g for 10 min at 4°C. The supernatant (2 mg of protein) was layered on a prechilled 10-50% linear sucrose gradient prepared in 5 mM TrisHCl, pH 7.5, 2.5 mM MgCl 2 , and 1.5 mM KCl, and then centrifuged in a Beckman SW41Ti rotor at 35,000 rpm for 2.5 h at 4°C. Gradients were fractionated while monitoring absorbance continuously at 254 nm with a effective against PIMexpressing human and mouse lym phoma cells and far superior to current PIM kinase inhibitors. Therapeutic blockade of translation affects several shortlived oncoproteins, including the PIM1/2 kinases and c-MYC, MCL1, and Cyclin D1. Silvestrol does not cause the feedback activation of upstream signaling molecules that has been seen upon rapamycin treatment (O'Reilly et al., 2006) . In sum mary, PIM kinase expression adversely affects outcomes in NHL, and targeting the translation of oncoproteins like PIM and cMyc effectively disables this critical output of converg ing oncogenic pathways.
MATERIALS AND METHODS
TMAs. TMAs were constructed from paraffinembedded tumor cores of 452 NHL patients treated at MSKCC since the mid1980s (173 DLBCL, 205 FL, 37 MCL, and 37 CLL/SLL). Use of tissue samples was approved by the Institutional Review Board and the Human Biospecimen Utilization Committee. All cancer biopsies were evaluated at MSKCC, and the histolog ical diagnosis was based on hematoxylin and eosin (H&E) staining. TMAs were constructed, stained, and scored as previously described (Hedvat et al., 2002) with antibodies against Pim1 and Pim2 (Cell Signaling Technology). Pim1 polyclonal antibody staining was performed at 1:100 dilution using the manufacturer's protocol, with secondary staining by OmniMap DAB anti Rb Detection kit (Ventana). Pim2 monoclonal antibody staining was per formed manually at 1:100 dilution in citric acid, pH 6, with rabbit secondary antibody and finished with DAB (3,3Diaminobenzidine). All TMA scoring was performed by an expert lymphoma hematopathologist.
Clinical data and analyses. Under MSKCC IRB waiver approval, clinical data were collected on patients whose tumors appear on the DLBCL and FL TMAs. Of the FL cases, we identified 66 whose disease required treat ment, whose specimen on the TMA was from before their initial therapy, and for whom treatment data and Pim scores were available. These cases were subjected to KaplanMeier TTE and OS analyses from initiation of therapy and date of diagnosis, respectively. Events were defined as progression of dis ease, death, or secondary malignancy. Logrank analysis was used to compare groups. The same analyses were performed on 116 DLBCL patients with available treatment data and whose biopsy sample on the TMA was from be fore initial therapy. PIM+ versus PIM patient groups were compared for age, sex, and additional clinical variables listed in Tables S1 and S2 based on data availability.  2 or fisher's exact test was used to compare categorical variables and Wilcoxon ranksum test was used to compare continuous variables.
Mouse lymphoma generation and analysis. All animal experiments were approved by the MSKCC Institutional Animal Care and Use Committee in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals. The Eµ-Myc model of aggressive lymphoma (Adams et al., 1985) and the VavPBcl2 model of follicular lym phoma (Egle et al., 2004) were adapted to the transplantation approach using retrovirally transduced HPCs (Wendel et al., 2004) . In brief, we isolated HPCs from the fetal livers of day 13.5-14.5 transgenic embryos and infected them with retroviral constructs coexpressing GFP and murine Pim2 or con stitutively active myristoylated AKT using the MSCVIRESGFP vector. The HPCs were then transplanted into syngeneic wildtype C57/B6 recipient animals after sublethal irradiation (same day 4.5G + 4.5G). We then tracked animals for tumor onset by observation, palpation, and blood smear evalua tion. Disease onset data were subjected to KaplanMeier analysis and the log rank (MantelCox) test for statistical significance. H&E, Ki67, TUNEL, phosphoAKT, phospho4EBP1, phosphoS6, Pim2, and surface marker analy sis were previously described (Mavrakis et al., 2008) . Eµ-Myc/Tsc2 / lym phomas are generated by crossing Eµ-Myc +/ mice to Tsc2 +/ mice . Double heterozygous offspring generate B cell tumors because of loss of heterozygosity at the Tsc2 locus, resulting in tumors that can be cultured ex vivo.
